Abu Dhabi-based pharmaceutical manufacturer Neopharma announces deal by its US subsidiary
Neopharma Inc, USA, a subsidiary of Abu Dhabi-based pharmaceutical manufacturer Neopharma, has announced that it has acquired a US-based antibiotic manufacturing factory.
It bought the Tennessee facility from Dr Reddy’s Laboratories Inc, a subsidiary of Dr Reddy’s Laboratories Ltd, a statement said.
The Tennessee site has had a long history first with the British drug maker GlaxoSmithKline (GSK) and then with Dr Reddy’s in manufacturing the brands Augmentin and Amoxil.
Neopharma said the sale will enable the facility to continue providing oral penicillin-containing antibacterial products to patients in the United States.
The 390,000 square-foot facility is dedicated to manufacturing and packaging oral-solid dose penicillin and has separate spaces for processing, packaging, development, printing, and warehousing, it added.
Neopharma said it has five pharmaceutical manufacturing facilities in three continents and serves over 50 countries with more than 100 products.
Dr BR Shetty, founder and chairman, Neopharma, said: “We are delighted to have this acquisition from Dr Reddy’s Laboratories as the acquisition follows similar acquisitions made in Japan, Brazil and India and is a part of the global expansion drive for Neopharma."For all the latest health tips & news from the UAE and Gulf countries, follow us on Twitter and Linkedin, like us on Facebook and subscribe to our YouTube page, which is updated daily.